{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:51:20Z","timestamp":1782305480950,"version":"3.54.5"},"posted":{"date-parts":[[2026,6,22]]},"group-title":"Cardiovascular Medicine","reference-count":24,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Digoxin use after the Norwood procedure has been associated with improved interstage survival in hypoplastic left heart syndrome and related conditions. Whether this benefit translates into improved longer-term outcomes through staged palliation remains unknown. We aimed to determine the association of digoxin use at Norwood discharge with transplant-free survival and Fontan completion.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective cohort study using the Pediatric Heart Network (PHN) Single Ventricle Reconstruction trial public dataset, including 549 infants enrolled at 15 North American centers between 2005 and 2008. Competing risk analysis was used to evaluate Fontan completion and Cox regression to assess death or transplantation within 6 years after the Norwood procedure. Mixed-effects models compared pre-Fontan hemodynamic and echocardiographic right ventricular indices between patients treated with and without digoxin after accounting for center clustering and adjustment for sex, shunt type, heart failure medications at Norwood discharge, and census block poverty level<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The 6-year cumulative incidence of Fontan completion was higher among patients discharged on digoxin than among those not receiving digoxin (82% vs 71%; p = 0.013). Competing-risk analysis accounting for death and transplant demonstrated a greater likelihood of Fontan completion among digoxin users (aHR 1.31; 95%CI 1.09\u20131.58; p = 0.005), without significant difference in the hazard of death or transplant (aHR 0.78; 95%CI 0.53\u20131.15; p = 0.208). No significant differences in pre-Fontan hemodynamic or echocardiographic indices were observed between groups. Initiation of digoxin post Stage II procedure was not associated with improved survival or likelihood to complete Fontan.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Digoxin use at the time of Norwood discharge was associated with a 30% greater likelihood of Fontan completion by 6 years, without accompanying improvement in transplant-free survival. These findings extend prior observations of improved interstage outcomes associated with digoxin use and suggest that treatment may facilitate progression through staged palliation.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Clinical perspective<\/jats:title>\n                  <jats:sec>\n                    <jats:label>1)<\/jats:label>\n                    <jats:title>What is new?<\/jats:title>\n                    <jats:p>Digoxin use during the interstage was associated with a greater likelihood of reaching Fontan completion within 6 years after Norwood discharge. However, this association was not accompanied by differences in right ventricular hemodynamic or echocardiographic indices at the time of Fontan evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:label>2)<\/jats:label>\n                    <jats:title>What are the clinical implications?<\/jats:title>\n                    <jats:p>These findings extend prior observations of improved interstage outcomes associated with digoxin use and provide important information for clinicians caring for patients with single-ventricle heart disease. Further studies are needed to clarify the mechanisms underlying this association and to identify patients most likely to benefit.<\/jats:p>\n                  <\/jats:sec>\n                <\/jats:sec>","DOI":"10.64898\/2026.06.17.26355912","type":"posted-content","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:45:16Z","timestamp":1782168316000},"source":"Crossref","is-referenced-by-count":0,"title":["Association of Digoxin Use at Norwood Discharge with Fontan Completion: A Study from the Pediatric Heart Network Public Dataset"],"prefix":"10.64898","author":[{"given":"Alaa","family":"Aljiffry","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"},{"name":"Chidren\u2019s Healthcare of Atlanta, Cardiology, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4915-462X","authenticated-orcid":false,"given":"Andrew","family":"Jergel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"},{"name":"Department of Pediatrics, Pediatric Biostatistics Core, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijin","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2243-8367","authenticated-orcid":false,"given":"Matthew E.","family":"Oster","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"},{"name":"Chidren\u2019s Healthcare of Atlanta, Cardiology, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4686-634X","authenticated-orcid":false,"given":"Lazaros","family":"Kochilas","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"},{"name":"Chidren\u2019s Healthcare of Atlanta, Cardiology, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026062405151055000_2026.06.17.26355912v1.1","doi-asserted-by":"crossref","unstructured":"Brown, D.W. , et al., Digoxin Use Is Associated With Reduced Interstage Mortality in Patients With No History of Arrhythmia After Stage I Palliation for Single Ventricle Heart Disease. J Am Heart Assoc, 2016. 5(1).","DOI":"10.1161\/JAHA.115.002376"},{"issue":"4","key":"2026062405151055000_2026.06.17.26355912v1.2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.athoracsur.2021.08.082","article-title":"Digoxin Associated With Greater Transplant-Free Survival in High-vs Low-Risk Interstage Patients","volume":"114","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"2026062405151055000_2026.06.17.26355912v1.3","doi-asserted-by":"crossref","unstructured":"Oster, M.E. , et al., Association of Digoxin With Interstage Mortality: Results From the Pediatric Heart Network Single Ventricle Reconstruction Trial Public Use Dataset. J Am Heart Assoc, 2016. 5(1).","DOI":"10.1161\/JAHA.115.002566"},{"issue":"20","key":"2026062405151055000_2026.06.17.26355912v1.4","doi-asserted-by":"crossref","first-page":"e029521","DOI":"10.1161\/JAHA.123.029521","article-title":"Association of Digoxin Use With Transplant-Free Interstage Survival in Infants Palliated With a Stage 1 Hybrid Procedure","volume":"12","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2026062405151055000_2026.06.17.26355912v1.5","first-page":"e33","article-title":"Evaluation and Management of Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease: A Scientific Statement From the American Heart Association","volume":"150","year":"2024","journal-title":"Circulation"},{"issue":"6","key":"2026062405151055000_2026.06.17.26355912v1.6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00246-018-1884-x","article-title":"Digoxin Use in Infants with Single Ventricle Physiology: Secondary Analysis of the Pediatric Heart Network Infant Single Ventricle Trial Public Use Dataset","volume":"39","year":"2018","journal-title":"Pediatr Cardiol"},{"issue":"23","key":"2026062405151055000_2026.06.17.26355912v1.7","doi-asserted-by":"crossref","first-page":"e021443","DOI":"10.1161\/JAHA.121.021443","article-title":"Association of Digoxin With Preserved Echocardiographic Indices in the Interstage Period: A Possible Mechanism to Explain Improved Survival?","volume":"10","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2026062405151055000_2026.06.17.26355912v1.8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/PCC.0000000000002946","article-title":"Association Between Digoxin Use and Cardiac Function in Infants With Single-Ventricle Congenital Heart Disease During the Interstage Period","volume":"23","year":"2022","journal-title":"Pediatr Crit Care Med"},{"issue":"6","key":"2026062405151055000_2026.06.17.26355912v1.9","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/chd.12834","article-title":"Trajectory of right ventricular indices is an early predictor of outcomes in hypoplastic left heart syndrome","volume":"14","year":"2019","journal-title":"Congenit Heart Dis"},{"issue":"7","key":"2026062405151055000_2026.06.17.26355912v1.10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.healun.2018.02.009","article-title":"Heart failure after the Norwood procedure: An analysis of the Single Ventricle Reconstruction Trial","volume":"37","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2026062405151055000_2026.06.17.26355912v1.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912461"},{"key":"2026062405151055000_2026.06.17.26355912v1.12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.006191"},{"key":"2026062405151055000_2026.06.17.26355912v1.13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029375"},{"issue":"17","key":"2026062405151055000_2026.06.17.26355912v1.14","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1161\/CIRCULATIONAHA.123.065192","article-title":"Longitudinal Follow-Up of Children With HLHS and Association Between Norwood Shunt Type and Long-Term Outcomes: The SVR III Study","volume":"148","year":"2023","journal-title":"Circulation"},{"key":"2026062405151055000_2026.06.17.26355912v1.15","doi-asserted-by":"crossref","unstructured":"Bucholz, E.M. , L.A. Sleeper , and J.W. Newburger , Neighborhood Socioeconomic Status and Outcomes Following the Norwood Procedure: An Analysis of the Pediatric Heart Network Single Ventricle Reconstruction Trial Public Data Set. J Am Heart Assoc, 2018. 7(3).","DOI":"10.1161\/JAHA.117.007065"},{"issue":"6","key":"2026062405151055000_2026.06.17.26355912v1.16","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jtcvs.2015.06.069","article-title":"Survival and right ventricular performance for matched children after stage-1 Norwood: Modified Blalock-Taussig shunt versus right-ventricle-to-pulmonary-artery conduit","volume":"150","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"2026062405151055000_2026.06.17.26355912v1.17","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.athoracsur.2023.04.020","article-title":"Procedure-Specific Center Volume and Mortality After Infantile Congenital Heart Surgery","volume":"116","year":"2023","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"2026062405151055000_2026.06.17.26355912v1.18","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.athoracsur.2023.08.006","article-title":"Contemporary Relationship Between Hospital Volume and Outcomes in Congenital Heart Surgery","volume":"116","year":"2023","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"2026062405151055000_2026.06.17.26355912v1.19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/chd.12760","article-title":"Perspective. Digoxin for interstage single ventricle patients: What could possibly go wrong?","volume":"14","year":"2019","journal-title":"Congenit Heart Dis"},{"key":"2026062405151055000_2026.06.17.26355912v1.20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ahj.2023.05.005","article-title":"Attributable mortality benefit of digoxin treatment in hypoplastic left heart syndrome after the Norwood operation: An instrumental variable-based analysis using data from the Pediatric Health Information Systems Database","volume":"263","year":"2023","journal-title":"Am Heart J"},{"key":"2026062405151055000_2026.06.17.26355912v1.21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.amjcard.2021.05.048","article-title":"Impact of Digoxin Use on Interstage Outcomes of Single Ventricle Heart Disease (From a NPC-QIC Registry Analysis)","volume":"154","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026062405151055000_2026.06.17.26355912v1.22","doi-asserted-by":"crossref","first-page":"100292","DOI":"10.1016\/j.jhlto.2025.100292","article-title":"The state of the art in medical therapies for pediatric heart failure","volume":"9","year":"2025","journal-title":"JHLT Open"},{"issue":"4","key":"2026062405151055000_2026.06.17.26355912v1.23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00246-021-02543-y","article-title":"Trends in Discharge Prescription of Digoxin After Norwood Operation: An Analysis of Data from the Pediatric Health Information System (PHIS) Database","volume":"42","year":"2021","journal-title":"Pediatr Cardiol"},{"issue":"8","key":"2026062405151055000_2026.06.17.26355912v1.24","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/14779072.2022.2103542","article-title":"Current evidence for pharmacologic therapy following stage 1 palliation for single ventricle congenital heart disease","volume":"20","year":"2022","journal-title":"Expert Rev Cardiovasc Ther"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.06.17.26355912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:15:31Z","timestamp":1782303331000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.06.17.26355912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":24,"URL":"https:\/\/doi.org\/10.64898\/2026.06.17.26355912","relation":{},"subject":[],"published":{"date-parts":[[2026,6,22]]},"subtype":"preprint"}}